PE20180571A1 - Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias - Google Patents
Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatoriasInfo
- Publication number
- PE20180571A1 PE20180571A1 PE2018000053A PE2018000053A PE20180571A1 PE 20180571 A1 PE20180571 A1 PE 20180571A1 PE 2018000053 A PE2018000053 A PE 2018000053A PE 2018000053 A PE2018000053 A PE 2018000053A PE 20180571 A1 PE20180571 A1 PE 20180571A1
- Authority
- PE
- Peru
- Prior art keywords
- interleukin
- peptide inhibitors
- inflammatory diseases
- treat inflammatory
- receptor peptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Se refiere a inhibidores peptidicos del receptor de interleucina 23 y comprende una secuencia de aminoacidos de cualquiera de las SEC ID N°: 365-370, 857-1029 y tiene como compuesto preferidos: [Palm]-[isoGlu]-[PEG4]-[Pen]-NTWQ-[Pen]-[Phe[4-(2-aminoeotxi)]-[2-Nal]-[Aib]-[Lys(Ac)]-NNNH2; entre otros. Tambien se refiere a una composicion farmaceutica que comprende el inhibidor peptidico y un portador, excipiente o diluyente farmaceuticamente aceptables y ademas esta composicion comprende un recubrimiento enterico, la presente invencion es util para colitis ulcerosa, enfermedad de Crohn, entre otros.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2015/040658 WO2016011208A1 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
US14/800,627 US9624268B2 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
US201562264820P | 2015-12-08 | 2015-12-08 | |
US201662281123P | 2016-01-20 | 2016-01-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20180571A1 true PE20180571A1 (es) | 2018-04-04 |
Family
ID=57757647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2018000053A PE20180571A1 (es) | 2015-07-15 | 2016-07-15 | Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP3341011A4 (es) |
JP (1) | JP6858174B2 (es) |
KR (1) | KR102513978B1 (es) |
CN (1) | CN108348580B (es) |
AU (1) | AU2016293619B2 (es) |
BR (1) | BR112018000691A2 (es) |
CA (1) | CA2991984A1 (es) |
CL (3) | CL2018000128A1 (es) |
CO (1) | CO2018000349A2 (es) |
CR (1) | CR20180029A (es) |
DO (1) | DOP2018000010A (es) |
EA (1) | EA035733B9 (es) |
EC (1) | ECSP18002929A (es) |
HK (2) | HK1257747A1 (es) |
IL (1) | IL256827A (es) |
MX (1) | MX2018000542A (es) |
NI (1) | NI201800008A (es) |
PE (1) | PE20180571A1 (es) |
PH (1) | PH12018500086A1 (es) |
SG (1) | SG10201912066SA (es) |
SV (1) | SV2018005614A (es) |
UA (1) | UA123772C2 (es) |
WO (1) | WO2017011820A2 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3176170T3 (en) | 2012-06-13 | 2019-01-28 | Incyte Holdings Corp | SUBSTITUTED TRICYCLIC RELATIONS AS FGFR INHIBITORS |
KR102236829B1 (ko) | 2013-03-15 | 2021-04-07 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | 헵시딘 유사체 및 이의 용도 |
SI2986610T1 (en) | 2013-04-19 | 2018-04-30 | Incyte Holdings Corporation | Bicyclic heterocycles as inhibitors of FGFR |
HRP20211448T1 (hr) | 2014-05-16 | 2021-12-24 | Protagonist Therapeutics, Inc. | Alfa4beta7 integrin tioeter peptidni antagonisti |
CN113563423A (zh) | 2014-07-17 | 2021-10-29 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
US10301371B2 (en) | 2014-10-01 | 2019-05-28 | Protagonist Therapeutics, Inc. | Cyclic monomer and dimer peptides having integrin antagonist activity |
SG11201702553RA (en) | 2014-10-01 | 2017-04-27 | Protagonist Therapeutics Inc | NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
EP3617205B1 (en) | 2015-02-20 | 2021-08-04 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
US20190002503A1 (en) | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
US10407468B2 (en) | 2016-03-23 | 2019-09-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing α4β7 peptide antagonists |
AU2018210174B2 (en) * | 2017-01-18 | 2022-04-07 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
TW201920234A (zh) | 2017-09-11 | 2019-06-01 | 美商領導醫療有限公司 | 類鴉片促效劑肽及其用途 |
CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
AU2019262579A1 (en) | 2018-05-04 | 2020-12-24 | Incyte Corporation | Salts of an FGFR inhibitor |
BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
TW202019948A (zh) * | 2018-07-12 | 2020-06-01 | 美商領導醫療有限公司 | 介白素-23受體之肽抑制劑及其治療發炎疾病之用途 |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
CN110015978B (zh) * | 2019-04-29 | 2021-03-19 | 康化(上海)新药研发有限公司 | O-[2-[[叔丁氧羰基]氨基]乙基]-n-[芴甲氧羰基]-l-酪氨酸的合成方法 |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3146390A1 (en) * | 2019-07-10 | 2021-01-14 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
WO2021076602A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
EP3819307A1 (en) * | 2019-11-07 | 2021-05-12 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤としての三環式複素環 |
JP2023505257A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤の誘導体 |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
MX2022008741A (es) * | 2020-01-15 | 2022-10-03 | Janssen Biotech Inc | Inhibidores de peptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
CN115279782A (zh) | 2020-01-15 | 2022-11-01 | 詹森生物科技公司 | 白介素-23受体的肽抑制剂及其用于治疗炎性疾病的用途 |
MX2023005994A (es) | 2020-11-20 | 2023-08-11 | Janssen Pharmaceutica Nv | Composiciones de inhibidores peptidicos del receptor de interleucina-23. |
EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
TW202321275A (zh) * | 2021-07-14 | 2023-06-01 | 美商健生生物科技公司 | 介白素—23受體之雙環肽抑制劑 |
TW202332682A (zh) | 2021-12-01 | 2023-08-16 | 丹麥商西蘭製藥公司 | 介白素—23受體之胜肽抑制劑 |
WO2023172648A2 (en) * | 2022-03-09 | 2023-09-14 | Glympse Bio, Inc. | Fluorogenic substrates for aminopeptidase detection in biofluids |
CN114751962B (zh) * | 2022-03-17 | 2023-11-07 | 北京大学 | 订书肽、其制备方法及其制药用途 |
WO2024003313A1 (en) | 2022-06-30 | 2024-01-04 | Sanofi | New peptides as selective il-23 receptor antagonists |
US20240218014A1 (en) * | 2022-11-21 | 2024-07-04 | Janssen Pharmaceutica Nv | Synthesis of a cyclic peptide |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5942492A (en) * | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
WO2008101017A2 (en) | 2007-02-15 | 2008-08-21 | Indiana Unversity Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
CA2692037A1 (en) * | 2007-07-06 | 2009-01-15 | Valorisation Hsj, Societe En Commandite | Il-23 receptor antagonists and uses thereof |
CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
US9523073B2 (en) | 2010-03-31 | 2016-12-20 | Medical Diagnostic Laboratories, Llc | Elisa for a naturally-occurring soluble truncated form of IL-23 receptor |
US9169292B2 (en) * | 2011-06-14 | 2015-10-27 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
US8946150B2 (en) | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
WO2015054500A2 (en) * | 2013-10-09 | 2015-04-16 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
CN113563423A (zh) * | 2014-07-17 | 2021-10-29 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
-
2016
- 2016-07-15 EP EP16825301.1A patent/EP3341011A4/en active Pending
- 2016-07-15 CR CR20180029A patent/CR20180029A/es unknown
- 2016-07-15 BR BR112018000691A patent/BR112018000691A2/pt active Search and Examination
- 2016-07-15 MX MX2018000542A patent/MX2018000542A/es unknown
- 2016-07-15 CN CN201680049562.2A patent/CN108348580B/zh active Active
- 2016-07-15 CA CA2991984A patent/CA2991984A1/en active Pending
- 2016-07-15 UA UAA201801482A patent/UA123772C2/uk unknown
- 2016-07-15 JP JP2018501178A patent/JP6858174B2/ja active Active
- 2016-07-15 AU AU2016293619A patent/AU2016293619B2/en active Active
- 2016-07-15 EA EA201890325A patent/EA035733B9/ru not_active IP Right Cessation
- 2016-07-15 SG SG10201912066SA patent/SG10201912066SA/en unknown
- 2016-07-15 WO PCT/US2016/042680 patent/WO2017011820A2/en active Application Filing
- 2016-07-15 KR KR1020187004612A patent/KR102513978B1/ko active IP Right Grant
- 2016-07-15 PE PE2018000053A patent/PE20180571A1/es unknown
-
2018
- 2018-01-09 PH PH12018500086A patent/PH12018500086A1/en unknown
- 2018-01-10 DO DO2018000010A patent/DOP2018000010A/es unknown
- 2018-01-10 IL IL256827A patent/IL256827A/en unknown
- 2018-01-11 NI NI201800008A patent/NI201800008A/es unknown
- 2018-01-15 CO CONC2018/0000349A patent/CO2018000349A2/es unknown
- 2018-01-15 EC ECIEPI20182929A patent/ECSP18002929A/es unknown
- 2018-01-15 SV SV2018005614A patent/SV2018005614A/es unknown
- 2018-01-15 CL CL2018000128A patent/CL2018000128A1/es unknown
- 2018-11-22 CL CL2018003322A patent/CL2018003322A1/es unknown
-
2019
- 2019-01-04 HK HK19100122.0A patent/HK1257747A1/zh unknown
- 2019-01-23 HK HK19101174.5A patent/HK1259149A1/zh unknown
-
2021
- 2021-02-09 CL CL2021000343A patent/CL2021000343A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20180571A1 (es) | Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias | |
CO2017006580A2 (es) | Anticuerpos humanos para hemaglutinina de influenza | |
SG10201810154WA (en) | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | |
UY35391A (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c | |
CL2016001405A1 (es) | A peptide mixture | |
SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
CR20160191A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
CL2018003319A1 (es) | Compuestos de mic-1 y usos de estos. | |
MX2013013913A (es) | Polipeptidos. | |
UY37456A (es) | Inmunoglobulinas y sus usos | |
UY33885A (es) | Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes | |
MY181181A (en) | Fgf21 derivatives and uses thereof | |
EA201591752A1 (ru) | Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы | |
AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
EA201792057A1 (ru) | Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы | |
IN2012DE00912A (es) | ||
CO2021014694A2 (es) | Una vacuna de subunidad para el tratamiento o la prevención de una infección del tracto respiratorio | |
EA201791696A1 (ru) | Композиция для лечения веноокклюзионной болезни печени | |
CO7151509A2 (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 | |
CO6592047A2 (es) | Formulación tópica oftálmica de péptidos | |
BR112017014737A2 (pt) | formulação de peptídeos inibidores de mk2 | |
CL2017003201A1 (es) | Variantes de il-37 | |
EA201792314A1 (ru) | Фармацевтическая комбинация эверолимуса и дактолисиба | |
EA201690966A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
ECSP13012552A (es) | Formas en estado sólido de un potente inhibidor del vch. |